Skip to Content
Merck
All Photos(1)

Documents

D7777

Sigma-Aldrich

Dulbecco′s Modified Eagle′s Medium - high glucose

With 4500 mg/L glucose, L-glutamine, and sodium pyruvate, without sodium bicarbonate, powder, suitable for cell culture

Synonym(s):

DME, DMEM

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352207
NACRES:
NA.75

Quality Level

form

powder

technique(s)

cell culture | mammalian: suitable

components

glucose: high
sodium pyruvate: yes
NaHCO3: no
HEPES: no
phenol red: yes
L-glutamine: yes

shipped in

ambient

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

Application

Dulbecco′s Modified Eagle′s Medium (DMEM) is a modification of Basal Medium Eagle (BME) that contains four-fold concentrations of the amino acids and vitamins. The original formulation contained 1000 mg/L of glucose and was used to culture embryonic mouse cells. Since then, it has been modified in several ways to support primary cultures of mouse and chicken cells, as well as a variety of normal and transformed cells. Each of these media offers a different combination of L-glutamine and sodium pyruvate. Additionally, the glucose levels have been raised to 4500 mg/L, contributing to the name "DMEM/High".

Quantity

Formulated to contain 13.5 grams of powder per liter of medium.

Reconstitution

Supplement with 3.7 g/L sodium bicarbonate

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 1


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Megan E Muroski et al.
Journal of the American Chemical Society, 136(42), 14763-14771 (2014-09-10)
Mesenchymal stem cells (MSC) have been identified as having great potential as autologous cell therapeutics to treat traumatic brain injury and spinal injury as well as neuronal and cardiac ischemic events. All future clinical applications of MSC cell therapies must
Jie Wang et al.
Molecular medicine reports, 22(2), 1111-1118 (2020-07-07)
Neuromyelitis optica (NMO) is a severe neurological demyelinating autoimmune disease that affects the optic nerves and spinal cord. There is currently no effective cure or therapy. Aquaporin‑4 (AQP4) is a known target of the autoimmune antibody NMO‑IgG. Therefore, binding of
Maria H Jäntti et al.
FEBS open bio, 8(5), 817-828 (2018-05-11)
Prostate cancer is one of the most common cancers in men. Although it has a relatively high 5-year survival rate, development of resistance to standard androgen-deprivation therapy is a significant clinical problem. Therefore, novel therapeutic strategies are urgently needed. The
Assaf Almog et al.
PLoS computational biology, 15(5), e1006934-e1006934 (2019-05-03)
Neural systems are organized in a modular way, serving multiple functionalities. This multiplicity requires that both positive (e.g. excitatory, phase-coherent) and negative (e.g. inhibitory, phase-opposing) interactions take place across brain modules. Unfortunately, most methods to detect modules from time series
Emilia Galli et al.
Cell transplantation, 28(4), 413-424 (2019-03-08)
Cerebral dopamine neurotrophic factor (CDNF) shows beneficial effects in rodent models of Parkinson's and Alzheimer's disease. The brain is a challenging target for protein therapy due to its exclusive blood-brain barrier. Hence, the therapeutic protein should be delivered directly to

Protocols

Powdered media and salt mixtures are extremely hygroscopic and should be protected from atmospheric moisture.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service